Obesity (drugs, devices, surgeries) keeps expanding

Like the average waistline of the world population, there is very little in the field of obesity that is not expanding — at least to varying degrees.  With the only exception being “malabsorption drugs”, which are declining, all segments of the obesity market are growing, from a low of 6.5% to a high of better than 65% annually.

Drugs for use in the clinical management of obesity, including the few that are approved and many that are pending (see also the recent FDA panel recommendation Orexigen’s Contrave drug), are  comprised of satiety drugs, malabsorption drugs, appetite-suppression drugs and combination drugs.  Devices include restrictive devices, artificial fullness devices, malabsorption devices, gastric emptying devices and appetite suppression devices.

But the field of obesity management is now, and will be, characterized by growing volumes of surgical procedures. The main types include Roux-en- Y gastric bypass, adjustable gastric band, biliopancreatic diversion with duodenal switch, and sleeve gastrectomy.  The exhibit below illustrates the growth of bariatric surgery procedures by type.

Global Trend in Metabolic/Bariatric Surgery, 2003-2013

Source: MedMarket Diligence, LLC; Report #S835.

Leave a Reply